NCT00884663

Candesartan Versus Propranolol for Migraine Prevention

Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Norwegian University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main aim of the present study is to compare candesartan with propranolol for migraine prophylaxis.

Detailed description

Candesartan was shown to be effective for migraine prophylaxis in a randomized double blind cross-over study published in 2003. The drug is now widely used for this purpose in many countries, although no confirmatory study has been published. The aims of the present study are: 1) to see if the results in the first candesartan study can be replicated in a new patient population, including patients with chronic migraine, and, 2) to perform a head-to-head comparison of candesartan 16 mg/day with standard treatment with propranolol 160 mg slow release. We also intend to study whether responsiveness to these drugs may be related to heart rate variability and baroreceptor sensitivity.

Conditions

• Migraine Without Aura
• Migraine With Aura
• Chronic Migraine

Interventions

Type	Name	Description
DRUG	Candesartan	Candesartan cilexitil tablets, 16 mg once daily
DRUG	propranolol	Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
DRUG	placebo	placebo tablets and capsules

Timeline

• Start date: 2009-04-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2009-04-21
• Last updated: 2013-12-24

Locations

1 site across 1 country: Norway